Analysts: Actavis-Allergan deal could create a marketing superpower

Valeant's ($VRX) been pursing Allergan ($AGN) for months now, but the California-based drugmaker may soon have another bid, too. Actavis ($ACT) is reportedly preparing to take its second stab at an Allergan deal, which could give Allergan some options. While the two potential transactions look comparable to Leerink Partners analysts Jason Gerberry and Seamus Fernandez from an accretion standpoint, the pair sees "less risk to Allergan brands suffering through the consolidation process" if Allergan combines with Actavis. Such a move "would unite two of the best marketing organizations in pharma," they wrote in a Wednesday note to shareholders. More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

Telehealth is surging during the pandemic, however, pharma companies’ place in the booming practice is still emerging.

Merck is expanding its cancer awareness effort with journalist Katie Couric to include survivorship and screening topics and a new podcast next month.